Astellas Pharma Inc. (ALPMY)

Trade ALPMY now with
10/31/2022 2:38:37 AM Astellas Pharma H1 Basic Core EPS 65.78 Yen Vs 53.30 Yen Last Year
10/12/2022 12:15:14 AM Astellas To Present Phase 3 Long-Term Safety Study Data Of Fezolinetant At North American Menopause Society Meeting
9/12/2022 9:02:23 AM Astellas Reports Results Of Trial Of PADCEV -KEYTRUDA &PADCEV As Monotherapy In First-Line Advanced Urothelial Cancer
8/18/2022 2:34:47 AM FDA Accepts Astellas' NDA For Fezolinetant For Treatment Of Vasomotor Symptoms Associated With Menopause
7/26/2022 4:22:18 AM Astellas, Seagen Announce Positive Topline Results For PADCEV With KEYTRUDA For Advanced Urothelial Cancer
7/5/2022 3:02:32 AM Mogrify , Astellas To Conduct Research On In Vivo Regenerative Medicine Approaches To Address Sensorineural Hearing Loss
6/26/2022 8:39:31 PM Astellas Pharma : FDA Places Clinical Hold On FORTIS Phase 1/2 Trial Of AT845 In Adults With Late-Onset Pompe Disease
6/1/2022 12:06:36 AM Astellas, GO Therapeutics Enter Strategic Research And License Deal To Develop Novel Antibodies For Immuno-Oncology
4/27/2022 2:53:51 AM Astellas Pharma FY EPS 103.03 Yen Vs 113.03 Yen Last Year